Rigel Pharmaceuticals (NASDAQ:RIGL) Earns Buy Rating from HC Wainwright

Posted by Brenda Bartman on May 22nd, 2026

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $57.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 95.27% from the company’s previous close.

Several other equities analysts also recently commented on RIGL. Zacks Research downgraded Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen downgraded Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Citigroup reiterated a “buy” rating and issued a $81.00 target price (up from $69.00) on shares of Rigel Pharmaceuticals in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $54.50.

View Our Latest Stock Analysis on RIGL

Rigel Pharmaceuticals Price Performance

Shares of Rigel Pharmaceuticals stock opened at $29.19 on Friday. The stock’s 50-day simple moving average is $28.52 and its 200-day simple moving average is $35.46. Rigel Pharmaceuticals has a 52 week low of $18.14 and a 52 week high of $52.24. The company has a market capitalization of $540.02 million, a price-to-earnings ratio of 1.56 and a beta of 1.21. The company has a quick ratio of 2.48, a current ratio of 2.62 and a debt-to-equity ratio of 0.04.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.80 by ($0.36). Rigel Pharmaceuticals had a net margin of 121.50% and a return on equity of 47.99%. The business had revenue of $58.82 million during the quarter, compared to analysts’ expectations of $62.40 million. As a group, analysts expect that Rigel Pharmaceuticals will post 3.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rigel Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. IFP Advisors Inc lifted its position in shares of Rigel Pharmaceuticals by 21.8% in the fourth quarter. IFP Advisors Inc now owns 2,264 shares of the biotechnology company’s stock worth $97,000 after buying an additional 405 shares in the last quarter. Y Intercept Hong Kong Ltd increased its stake in Rigel Pharmaceuticals by 1.9% during the first quarter. Y Intercept Hong Kong Ltd now owns 28,803 shares of the biotechnology company’s stock worth $779,000 after acquiring an additional 546 shares during the last quarter. Rhumbline Advisers increased its stake in Rigel Pharmaceuticals by 2.1% during the second quarter. Rhumbline Advisers now owns 27,065 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 555 shares during the last quarter. Range Financial Group LLC increased its stake in Rigel Pharmaceuticals by 1.2% during the fourth quarter. Range Financial Group LLC now owns 45,938 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 561 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in Rigel Pharmaceuticals by 4.0% during the fourth quarter. Deutsche Bank AG now owns 14,655 shares of the biotechnology company’s stock worth $628,000 after acquiring an additional 570 shares during the last quarter. 66.23% of the stock is currently owned by hedge funds and other institutional investors.

About Rigel Pharmaceuticals

(Get Free Report)

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).